Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Receivables (2016 - 2025)

Historic Receivables for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to $232298.0.

  • Regen BioPharma's Receivables rose 8994.42% to $232298.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $232298.0, marking a year-over-year increase of 8994.42%. This contributed to the annual value of $204873.0 for FY2025, which is 11594.45% up from last year.
  • Latest data reveals that Regen BioPharma reported Receivables of $232298.0 as of Q4 2025, which was up 8994.42% from $204873.0 recorded in Q3 2025.
  • Regen BioPharma's Receivables' 5-year high stood at $295466.0 during Q2 2022, with a 5-year trough of $12298.0 in Q4 2023.
  • Its 5-year average for Receivables is $156991.9, with a median of $158042.0 in 2021.
  • As far as peak fluctuations go, Regen BioPharma's Receivables plummeted by 9066.2% in 2023, and later skyrocketed by 89445.44% in 2024.
  • Over the past 5 years, Regen BioPharma's Receivables (Quarter) stood at $240617.0 in 2021, then plummeted by 45.27% to $131698.0 in 2022, then plummeted by 90.66% to $12298.0 in 2023, then soared by 894.45% to $122298.0 in 2024, then soared by 89.94% to $232298.0 in 2025.
  • Its last three reported values are $232298.0 in Q4 2025, $204873.0 for Q3 2025, and $177147.0 during Q2 2025.